# The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

> **NCT02965859** · PHASE2 · UNKNOWN · sponsor: **Guangzhou Yipinhong Pharmaceutical CO.,LTD** · enrollment: 180 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Metacavir Enteric-coated Capsules 80mg
- **DRUG:** Metacavir Enteric-coated Capsules 160mg
- **DRUG:** Metacavir Enteric-coated Capsules 320mg
- **DRUG:** Metacavir Enteric-coated Capsules Placebo 240mg
- **DRUG:** Metacavir Enteric-coated Capsules Placebo 160mg
- **DRUG:** Metacavir Enteric-coated Capsules Placebo 320mg
- **DRUG:** Adefovir Dipivoxil Capsule10mg
- **DRUG:** Adefovir Dipivoxil Capsule Placebo 10mg

## Key facts

- **NCT ID:** NCT02965859
- **Lead sponsor:** Guangzhou Yipinhong Pharmaceutical CO.,LTD
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-12
- **Primary completion:** 2018-12
- **Final completion:** —
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2016-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02965859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02965859, "The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02965859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*